TL;DR
Picard Medical and SynCardia are set to unveil their next-generation Emperor Total Artificial Heart at IEEE EMBC 2026. The presentation marks a significant step in artificial heart development, with potential implications for patients with end-stage heart failure.
Picard Medical and SynCardia are preparing to present their next-generation Emperor Total Artificial Heart at the IEEE Engineering in Medicine and Biology Conference (EMBC) 2026. This event marks a key milestone in artificial heart technology development, showcasing innovations aimed at improving patient outcomes for those with severe heart failure. The presentation is confirmed and scheduled for the conference, which is set to take place in 2026.
The Emperor Total Artificial Heart is a device designed to replace the entire heart in patients suffering from end-stage heart failure. The companies involved, Picard Medical and SynCardia, announced that they will unveil their next-generation model at the upcoming IEEE EMBC 2026. This new version is expected to incorporate advanced features aimed at improving durability, biocompatibility, and ease of implantation, although specific technical details are not yet publicly confirmed.
According to a press release from GlobeNewswire, the presentation will highlight innovations in device design, including potential improvements in patient mobility and reduced reliance on external power sources. Both companies emphasized their commitment to advancing artificial heart technology to better serve patients awaiting heart transplants or unsuitable for traditional treatments.
While the companies have not disclosed detailed specifications of the new device, industry analysts suggest that the next-generation Emperor could set new standards in total artificial heart performance. The companies also indicated that they are engaged in ongoing clinical evaluations, with regulatory pathways potentially underway following the conference presentation.
Potential Impact on Heart Failure Treatments
The unveiling of the next-generation Emperor Total Artificial Heart could represent a major advancement in the treatment of end-stage heart failure. If the new device demonstrates improved durability, patient quality of life, and ease of use, it may expand options for patients who currently face limited choices. The development signals ongoing innovation in the field of artificial organs, which could lead to broader adoption and faster regulatory approval.
Furthermore, this presentation underscores the growing role of robotic and implantable artificial organs in modern medicine, potentially reducing reliance on donor hearts and addressing shortages in transplant availability. The companies involved aim to position themselves as leaders in this emerging market, which could influence future research, funding, and clinical practices.
artificial heart replacement device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Advances in Artificial Heart Technology Since 2023
Since 2023, artificial heart technology has seen incremental improvements, including the approval of devices like SynCardia’s existing total artificial heart for broader clinical use. The companies involved have been investing in research to enhance device longevity, patient mobility, and biocompatibility. The IEEE EMBC conference remains a key platform for unveiling innovations in biomedical engineering, with previous presentations leading to regulatory reviews and clinical trials.
SynCardia, in particular, has been a pioneer in total artificial hearts, with the SynCardia Total Artificial Heart approved for use in certain regions. The upcoming presentation of the next-generation Emperor aligns with ongoing industry efforts to improve upon existing devices and address current limitations, such as size, power management, and infection risks.
“Our next-generation Emperor device represents a significant step forward in artificial heart technology, with innovations aimed at enhancing patient outcomes and device longevity.”
— Dr. Lisa Chen, Chief Engineer at Picard Medical
total artificial heart implant
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Details of the New Device Remain Under Wraps
Specific technical features, clinical trial results, and regulatory status of the next-generation Emperor have not yet been publicly disclosed. It is unclear when the device will be available for wider clinical use or its exact performance benchmarks.
Industry experts note that further testing and regulatory review will be necessary before the device can be adopted broadly, and the companies have not yet announced timelines beyond the conference presentation.
next-generation artificial heart
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Upcoming Presentation and Future Regulatory Steps
The IEEE EMBC 2026 conference will serve as the platform for the official unveiling of the next-generation Emperor Total Artificial Heart. Following this, the companies are expected to publish detailed technical data and initiate discussions with regulators. Clinical trials may be launched or expanded based on initial findings presented at the conference. The timeline for potential market approval remains to be seen.
artificial heart for end-stage heart failure
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the Emperor Total Artificial Heart?
The Emperor Total Artificial Heart is a device designed to replace the entire heart in patients with severe heart failure, providing a mechanical solution for heart function support.
When will the new device be available for patients?
The device will be publicly presented at IEEE EMBC 2026, but its availability for clinical use depends on subsequent testing, regulatory approval, and manufacturing timelines, which have not yet been announced.
How does the new Emperor differ from existing artificial hearts?
Specific differences are not yet publicly detailed, but the new model is expected to feature improvements in durability, size, power management, and biocompatibility based on preliminary industry hints.
What are the potential benefits for patients?
If successful, the new device could offer longer-lasting support, improved quality of life, and reduced complications compared to current artificial heart options.
Will this device reduce the need for heart transplants?
Potentially, yes. Advanced artificial hearts could serve as a long-term solution or bridge to transplant, helping address organ shortages and expanding treatment options.
Source: primary
